Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia
- 28 July 2020
- journal article
- research article
- Published by Walter de Gruyter GmbH in cclm
- Vol. 58 (8), 1214-1222
- https://doi.org/10.1515/cclm-2019-1172
Abstract
Background Monitoring of molecular response (MR) using quantitative polymerase chain reaction (PCR) for BCR-ABL1 is a pivotal tool for guiding tyrosine kinase inhibitor therapy and the long-term follow-up of patients with chronic myeloid leukemia (CML). Results of MR monitoring are standardized according to the International Scale (IS), and specific time-dependent molecular milestones for definition of optimal response and treatment failure have been included in treatment recommendations. The common practice to use peripheral blood (PB) instead of bone marrow (BM) aspirate to monitor the MR monitoring in CML has been questioned. Some studies described differences between BCR-ABL1 levels in paired PB and BM specimens. Methods We examined 631 paired PB and BM samples from 283 CML patients in a retrospective single-center study using an IS normalized quantitative reverse transcription (qRT)-PCR assay for quantification of BCR-ABL1IS. Results A good overall concordance of BCR-ABL1IS results was found, a systematic tendency towards higher BCR-ABL1IS levels in PB was observed in samples of CML patients in a major MR. This difference was most pronounced in patients treated with imatinib for at least 1 year. Importantly, the difference resulted in a significantly lower rate of deep MR when BCR-ABL1IS was assessed in the PB compared to BM aspirates. Conclusions In summary, our data suggest that the classification of deep MR in patients with CML is more stringent in PB than in BM. Our study supports the current practice to primarily use PB for long-term molecular follow-up monitoring in CML.Keywords
This publication has 25 references indexed in Scilit:
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Blood, 2013
- The differences and correlations of BCR‐ABL transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemiaAmerican Journal of Hematology, 2012
- Standardized definitions of molecular response in chronic myeloid leukemiaLeukemia, 2012
- Peripheral blood vs. bone marrow for molecular monitoring of BCR‐ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipientsInternational Journal of Laboratory Hematology, 2010
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNetJournal of Clinical Oncology, 2009
- Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapyInternational Journal of Hematology, 2008
- Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsBlood, 2006
- Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patientsAnnals of Oncology, 2006
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2003